SCHEMBL8863552

SCHEMBL8863552

CC(CN)CON

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4660908 0.97
Sulfuric Acid SCHEMBL8753080 0.85 CA1 (0.38)
SCHEMBL3577665 0.83
Bromide SCHEMBL3583647 0.80 CA1 (0.39)
SCHEMBL4545489 0.75
SCHEMBL1508181 0.75
SCHEMBL2627432 0.75
SCHEMBL5200468 0.75
SCHEMBL24164767 0.73
SCHEMBL21526279 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5610195-A ANTITUMOR AGENTS CIBA-GEIGY CORPORATION (US) 1997-03-11 US claimed
EP-0644873-A1 ORNITHINE DECARBOXYLASE INHIBITING BRANCHED AMINOOXY AMINO ALKANE DERIVATIVES. CIBA GEIGY AG (CH) 1995-03-29 EP claimed
WO-1994024094-A1 ORNITHINE DECARBOXYLASE INHIBITING BRANCHED AMINOOXY AMINO ALKANE DERIVATIVES CIBA-GEIGY AG (CH) 1994-10-27 WO claimed
EP-2740723-A2 SULPHAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Korea Research Institute of Chemical Technology (KR) 2014-06-11 EP disclosed